Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine
Gilead
['axi-cel', 'lymsm', 'dlbcl']
conclusion: axi-cel should be standard second-line treatment for patients with dlbcl who relapse within the first year. hopefully this os benefit leads to regulatory approval in 2l context in many places full paper out at : #asco23 #lymsm 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem